This open-label trial (n=27) investigates how MDMA (105mg/70kg) is metabolised by the body and how differences in genes and sex (male/female) influence this.
Conducted by Parc de Salut Mar in collaboration with the National Institute on Drug Abuse (NIDA), the study assessed the role of CYP2D6, CYP3A4, CYP1A2, and catechol-O-methyltransferase (COMT) in MDMA metabolism, along with gender differences and the influence of genetic polymorphisms (CYP2D6, COMT, SERT) on MDMA’s pharmacokinetics and effects. Healthy male and female adults with prior MDMA use received a single MDMA dose (1.5 mg/kg; range 75-100 mg). The study measured MDMA and metabolite concentrations in plasma and urine, as well as physiological and subjective effects, to better understand individual variations in MDMA metabolism.
Trial Details
The purpose of this study are: 1. to evaluate the involvement of CYP2D6, CYP3A4 and CYP1A2 (through dextromethorphan and caffeine challenges), and catechol-O-methyltransferase (COMT)in MDMA metabolism 2. to evaluate gender differences in the human pharmacology of MDMA 3. to study the influence of some genetic polymorphisms (CYP2D6, COMT, SERT) in the effects and pharmacokinetics of MDMA.Trial Number NCT01447472
Sponsors & Collaborators
Parc de Salut MarThis company doesn't have a full profile yet, it is linked to a clinical trial.
National Institute on Drug Abuse
This company doesn't have a full profile yet, it is linked to a clinical trial.